BRIEF published on 01/08/2025 at 14:35, 10 months 28 days ago Health Canada Approves Formycon's Biosimilar FYB202/Otulfi® Healthcare Costs Biosimilar Formycon Ustekinumab Canada Approval
PRESS RELEASE published on 01/08/2025 at 14:30, 10 months 28 days ago Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Formycon and Fresenius Kabi Canada obtain Health Canada's approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Health Canada Approval Biosimilar Formycon Stelara Fresenius Kabi Canada
BRIEF published on 12/11/2024 at 16:31, 11 months 25 days ago Formycon AG Maintains Strong Growth Prospects Amidst Challenging Market Conditions FDA Approval Revenue Decline Formycon AG Biosimilars Stelara Launch
PRESS RELEASE published on 12/11/2024 at 16:26, 11 months 25 days ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF published on 12/09/2024 at 06:35, 11 months 27 days ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
PRESS RELEASE published on 12/09/2024 at 06:30, 11 months 27 days ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
BRIEF published on 12/05/2024 at 13:00, 1 year ago Formycon Joins the SDAX of the German Stock Exchange Market Strategy Biosimilars SDAX Formycon German Stock Exchange
PRESS RELEASE published on 12/05/2024 at 12:55, 1 year ago Formycon joins the SDAX of the German Stock Exchange Formycon AG joins the SDAX of the German Stock Exchange, enhancing share attractiveness and visibility in the capital market. Key milestone in the company's growth strategy Formycon AG Biosimilars Capital Market SDAX German Stock Exchange
BRIEF published on 11/28/2024 at 06:35, 1 year ago Formycon Reports Continued Growth in 2024 Nine-Month Results Financial Results Market Position FDA Approval Biosimilars Strategic Growth
PRESS RELEASE published on 11/28/2024 at 06:30, 1 year ago Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes Formycon reports nine-month results for 2024 with operational successes and growth trajectory, including product approvals and new biosimilar candidates Biosimilars Growth Trajectory Formycon Nine-month Results Operational Successes
Published on 12/05/2025 at 19:50, 21 minutes ago Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 51 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 1 hour 26 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:20, 1 hour 51 minutes ago NuRAN Announces Intention to Complete Consolidation in Preparation to the Restructuring Transaction
Published on 12/05/2025 at 18:00, 2 hours 11 minutes ago SMX: A New Supply Chain Reality in the World's Four Largest Markets
Published on 12/05/2025 at 18:58, 1 hour 13 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 1 hour 56 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 2 hours 25 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 2 hours 53 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 11 hours 26 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 1 day 2 hours ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 1 day 2 hours ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
